Raymond James analyst Elliot Wilbur maintained a Buy rating on Antares Pharma (ATRS) yesterday. The company’s shares closed last Monday at $2.86.
According to TipRanks.com, Wilbur has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 42.9% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Amneal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Antares Pharma with a $4.50 average price target, which is a 55.2% upside from current levels. In a report issued on November 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.
See today’s analyst top recommended stocks >>
Based on Antares Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $40 million and net profit of $5 million. In comparison, last year the company earned revenue of $34.31 million and had a net profit of $1.04 million.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.
